Lantern Pharma Inc.
LTRN
$4.44
-$0.13-2.85%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.54% | 22.78% | -30.39% | 9.15% | 8.85% |
| Total Depreciation and Amortization | 2.10% | 2.34% | 6.89% | 1,013.95% | 4.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -204.79% | -92.63% | 356.50% | -416.89% | -72.07% |
| Change in Net Operating Assets | 452.68% | -94.74% | 243.64% | -203.15% | -114.15% |
| Cash from Operations | 10.02% | -10.17% | 28.85% | -7.55% | -69.16% |
| Capital Expenditure | 100.00% | 61.29% | -3.33% | 30.23% | -95.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 10.88% | -6.08% | 404.87% | 445.50% | 64.30% |
| Cash from Investing | 10.93% | -6.03% | 406.73% | 436.62% | 63.66% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -100.00% | -- | -100.00% |
| Foreign Exchange rate Adjustments | 896.43% | 104.17% | -514.81% | 43.36% | 215.31% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 72.10% | -91.57% | 87.86% | 9.43% | -50.33% |